ADMA Biologics rebuts short seller report, labeling claims misleading
ADMA Biologics (NASDAQ:ADMA), a U.S.-based commercial biopharmaceutical company specializing in the manufacture and marketing of specialty biologics, issued a formal statement on Wednesday addressing a critical report published on March 24, 2026, by Culper Research.











